Compare · AZN vs COLL
AZN vs COLL
Side-by-side comparison of AstraZeneca PLC (AZN) and Collegium Pharmaceutical Inc. (COLL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and COLL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $546.72B, about 542.7x COLL ($1.01B).
- Over the past year, AZN is down 6.3% and COLL is up 5.7% - COLL leads by 12.0 points.
- AZN has been more active in the news (24 items in the past 4 weeks vs 20 for COLL).
- AZN has more recent analyst coverage (25 ratings vs 20 for COLL).
- Company
- AstraZeneca PLC
- Collegium Pharmaceutical Inc.
- Price
- $176.33-0.62%
- $31.06+1.82%
- Market cap
- $546.72B
- $1.01B
- 1M return
- -3.87%
- -10.21%
- 1Y return
- -6.35%
- +5.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2015
- News (4w)
- 24
- 20
- Recent ratings
- 25
- 20
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Latest AZN
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest COLL
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- Collegium to Participate in 2026 Jefferies Global Healthcare Conference
- Director Freund John Gordon sold $681 worth of shares (20 units at $34.05), decreasing direct ownership by 0.02% to 83,952 units (SEC Form 4)
- Director Bohlin Garen G was granted 8,741 shares, increasing direct ownership by 14% to 71,000 units (SEC Form 4)
- Director Freund John Gordon was granted 8,741 shares, exercised 8,700 shares at a strike of $16.49 and sold $142,547 worth of shares (4,127 units at $34.54), increasing direct ownership by 19% to 83,972 units (SEC Form 4)
- Director Paya Carlos V was granted 8,741 shares, increasing direct ownership by 45% to 28,323 units (SEC Form 4)
- Director Lurker Nancy was granted 8,741 shares, increasing direct ownership by 49% to 26,758 units (SEC Form 4)
- Director Balice-Gordon Rita J. was granted 8,741 shares, increasing direct ownership by 17% to 61,370 units (SEC Form 4)
- Director Glancy Donovan Michael was granted 17,482 shares (SEC Form 4)